丙酸氟替卡松联合酮替芬对小儿过敏性哮喘的临床疗效及安全性评估  

Efficacy and safety of fluticasone propionate combined with ketotifen in pediatric allergic asthma

在线阅读下载全文

作  者:吉小军 张明敏 陈袁园 Ji Xiao-jun;Zhang Ming-min;Chen Yuan-yuan(Department of Pediatrics,Hai'an People's Hospital,Hai'an 226600,China)

机构地区:[1]海安市人民医院儿科,海安226600

出  处:《中国药物应用与监测》2024年第5期622-625,共4页Chinese Journal of Drug Application and Monitoring

摘  要:目的探究丙酸氟替卡松联合酮替芬对小儿过敏性哮喘的临床疗效并分析其安全性。方法纳入2020年1月至2022年1月在海安市人民医院就诊的102例小儿过敏性哮喘患儿作为研究对象,按照随机数字表法分为试验组与对照组各51例,对照组采用丙酸氟替卡松治疗,试验组采用丙酸氟替卡松联合酮替芬治疗,对比两组患儿的症状改善情况、血清学相关指标、肺功能指标和不良反应发生率。结果治疗后两组儿童哮喘控制测试量表(C-ACT)评分均较治疗前提高(P<0.05),且试验组C-ACT评分(23.27±3.29)分高于对照组(21.62±2.83)分(t=2.715,P<0.05)。两组患儿治疗后用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、最高呼气流量峰值(PEF)均较治疗前上升(P<0.05),试验组FVC、FEV_(1)、PEF指标[分别为(2.16±0.47)L、(1.98±0.34)L、(3.43±1.06)L·s^(-1)]均高于对照组[分别为(1.85±0.54)L、(1.75±0.31)L、(2.92±0.95)L·s^(-1)](t=3.092、t=3.259、t=2.559,均P<0.05)。两组患儿血清免疫球蛋白E(IgE)和白细胞介素-6(IL-6)水平均较治疗前下降(P<0.05),试验组IgE、IL-6水平[分别为(135.62±23.70)μg·L^(-1)、(7.24±1.41)ng·L^(-1)]均低于对照组[分别为(152.46±22.38)μg·L^(-1)、(9.73±1.38)ng·L^(-1)](t=3.689、t=8.179,均P<0.05)。两组不良反应发生率差异无统计学意义(9.80%vs 15.69%,χ^(2)=0.793,P>0.05)。结论丙酸氟替卡松联合酮替芬对小儿过敏性哮喘具有良好的治疗效果,可改善患儿的哮喘症状和肺功能,降低患儿体内血清中Ig E、IL-6水平,且安全性良好。Objective To investigate the clinical efficacy and analyze the safety of fluticasone propionate combined with ketotifen in pediatric allergic asthma.Methods A total of102children with allergic asthma admitted to Hai’an People’s Hospital from January 2020 to January 2022 were selected as the study subjects and divided into the control group and trial group according to the randomized numerical table method,with 51 in each group.The patients in the control group were treated with fluticasone propionate and those in the trial group with fluticasone propionate combined with ketotifen.The symptomatic improvement,pulmonary function indexes,serologic indexes and the incidence of adverse reactions were compared between the two groups.Results The Childhood Asthma Control Test Scale(C-ACT)scores increased in both groups after treatment,and the trial group's score was higher than the control group's score((23.27±3.29)scoresvs(21.62±2.83)scores,t=2.715,P<0.05).The first-second expiratory volume with exertion(FEV_(1)),expiratory lung capacity(FVC),and peak expiratory flow(PEF)of the highest expiratory flow rate(PEF)increased in both groups after treatment,and these indexes were(2.16±0.47)L,(1.98±0.34)Land(3.43±1.06)L·s^(-1) in the trial group,which were higher than those of(1.85±0.54)L,(1.75±0.31)L and(2.92±0.95)L·s^(-1) in the control(t=3.092,3.259,2.559,all P<0.05).The serum immunoglobulin E(IgE)and interleukin-6(IL-6)levels were decreased in both groups,and the levels of the 2indicators were(135.62±23.70)μg·L^(-1) and(7.24±1.41)ng·L^(-1) in the trial group,which were lower than those of(152.46±22.38)μg·L^(-1) and(9.73±1.38)ng·L^(-1) in the control(t=3.689,2.559,both P<0.05).The incidence of adverse reactions was not significantly different between the two groups(7.84%vs 11.76%,χ^(2)=0.793,P>0.05).Conclusion Fluticasone propionate combined with ketotifen has a good therapeutic effect on paediatric allergic asthma since it can improve the asthma symptoms and lung function of children and reducethe se

关 键 词:过敏性哮喘 儿童 丙酸氟替卡松 酮替芬 临床疗效 安全性 

分 类 号:R725.6[医药卫生—儿科] R969.4[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象